What is the MACE Score?
MACE is not a single standardized score, but rather an acronym for Major Adverse Cardiovascular Events—a composite outcome measure used to assess cardiovascular risk, with definitions varying significantly across clinical contexts and studies.
Understanding MACE as an Outcome Measure
MACE represents a composite endpoint rather than a unified scoring system. The term encompasses serious cardiovascular complications, but its specific components differ depending on the clinical setting and study design 1, 2.
Core Components in Acute Coronary Syndromes
In the context of acute coronary syndromes (ACS), MACE typically includes 1:
- Cardiovascular death
- Myocardial infarction (MI)
- Stroke
- Urgent revascularization
The 2025 ACC/AHA/ACEP guidelines emphasize that clinical decision pathways incorporating serial troponin testing provide high negative predictive value (>99.5%) for MACE, helping identify very low-risk patients 1.
Risk Stratification Tools (Not "MACE Scores")
Rather than a "MACE score," clinicians use validated risk stratification tools to predict MACE probability 1:
For ACS patients, the guidelines recommend:
GRACE Risk Score 2.0 - Predicts in-hospital, 6-month, 1-year, and 3-year death or death/MI
- Variables: age, Killip class, blood pressure, heart rate, ST-segment deviation, cardiac arrest, serum creatinine
- Superior to physician subjective assessment
TIMI Risk Score - Available for both NSTEMI and STEMI
- NSTEMI version: Predicts 14-day death, MI, or urgent revascularization
- STEMI version: Predicts 30-day all-cause death
Important caveat: These scores stratify risk in patients with suspected or confirmed ACS—they are not diagnostic tools 1.
In Chronic Coronary Syndromes
For stable coronary disease, MACE risk estimation guides decisions about functional imaging and revascularization 2. Imaging modalities like PET and CMR are recommended specifically to "estimate the risk of MACE" in patients with moderate-to-high pre-test probability of obstructive coronary disease 2.
Clinical Application Algorithm
When encountering "MACE" in clinical practice:
Identify the clinical context - Is this acute coronary syndrome, chronic coronary disease, post-procedural risk, or another setting?
Use validated risk scores rather than searching for a "MACE score":
Recognize definition variability - Recent research shows MACE definitions vary widely across studies, with no standardized three-point definition consistently applied 3, 4
Apply context-specific definitions - Post-liver transplant MACE includes heart failure and arrhythmias prominently 4, while post-PCI MACE focuses on ischemic events 5
Common Pitfalls
- Assuming MACE is a single validated score - It is not; it's an outcome measure with variable definitions
- Using risk scores diagnostically - GRACE and TIMI scores only stratify risk in confirmed/suspected ACS, not for diagnosis 1
- Ignoring local assay characteristics - When using clinical decision pathways, know your institution's troponin assay specifications (conventional vs. high-sensitivity, sex-specific cutoffs) 1
- Expecting universal definitions - MACE components differ by specialty and study design; always verify what specific events are included 4
The evidence demonstrates that while MACE serves as a crucial endpoint for cardiovascular risk assessment, clinicians should rely on validated, context-specific risk stratification tools (GRACE, TIMI) rather than seeking a singular "MACE score" 1.